Biohaven Pharmaceutical Holding Stock Probability of Future Stock Price Finishing Under 44.93
| BHVN Stock | USD 46.01 0.37 0.80% |
Biohaven |
Biohaven Pharmaceutical Target Price Odds to finish below 44.93
The tendency of Biohaven Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 44.93 or more in 90 days |
| 46.01 | 90 days | 44.93 | about 37.28 |
Based on a normal probability distribution, the odds of Biohaven Pharmaceutical to drop to $ 44.93 or more in 90 days from now is about 37.28 (This Biohaven Pharmaceutical Holding probability density function shows the probability of Biohaven Stock to fall within a particular range of prices over 90 days) . Probability of Biohaven Pharmaceutical price to stay between $ 44.93 and its current price of $46.01 at the end of the 90-day period is about 7.28 .
Given the investment horizon of 90 days Biohaven Pharmaceutical has a beta of 0.93 suggesting Biohaven Pharmaceutical Holding market returns are highly reactive to returns on the market. As the market goes up or down, Biohaven Pharmaceutical is expected to follow. Additionally Biohaven Pharmaceutical Holding has an alpha of 0.1163, implying that it can generate a 0.12 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Biohaven Pharmaceutical Price Density |
| Price |
Predictive Modules for Biohaven Pharmaceutical
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Biohaven Pharmaceutical. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biohaven Pharmaceutical's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Biohaven Pharmaceutical Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Biohaven Pharmaceutical is not an exception. The market had few large corrections towards the Biohaven Pharmaceutical's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Biohaven Pharmaceutical Holding, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Biohaven Pharmaceutical within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.12 | |
β | Beta against Dow Jones | 0.93 | |
σ | Overall volatility | 5.76 | |
Ir | Information ratio | 0.03 |
Biohaven Pharmaceutical Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Biohaven Pharmaceutical for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Biohaven Pharmaceutical can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Biohaven Pharmaceutical had very high historical volatility over the last 90 days | |
| Biohaven Pharmaceutical Holding currently holds 30.88 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. Biohaven Pharmaceutical has a current ratio of 0.7, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biohaven Pharmaceutical's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (408.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biohaven Pharmaceutical Holding currently holds about 23.21 M in cash with (331.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.48. | |
| Biohaven Pharmaceutical has a poor financial position based on the latest SEC disclosures | |
| Over 87.0% of Biohaven Pharmaceutical shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Biohaven shares retains overweight rating on clinical trial |
Biohaven Pharmaceutical Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Biohaven Stock often depends not only on the future outlook of the current and potential Biohaven Pharmaceutical's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Biohaven Pharmaceutical's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 71.2 M | |
| Cash And Short Term Investments | 381.8 M |
Biohaven Pharmaceutical Technical Analysis
Biohaven Pharmaceutical's future price can be derived by breaking down and analyzing its technical indicators over time. Biohaven Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Biohaven Pharmaceutical Holding. In general, you should focus on analyzing Biohaven Stock price patterns and their correlations with different microeconomic environments and drivers.
Biohaven Pharmaceutical Predictive Forecast Models
Biohaven Pharmaceutical's time-series forecasting models is one of many Biohaven Pharmaceutical's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Biohaven Pharmaceutical's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Biohaven Pharmaceutical
Checking the ongoing alerts about Biohaven Pharmaceutical for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Biohaven Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Biohaven Pharmaceutical had very high historical volatility over the last 90 days | |
| Biohaven Pharmaceutical Holding currently holds 30.88 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. Biohaven Pharmaceutical has a current ratio of 0.7, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biohaven Pharmaceutical's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (408.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biohaven Pharmaceutical Holding currently holds about 23.21 M in cash with (331.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.48. | |
| Biohaven Pharmaceutical has a poor financial position based on the latest SEC disclosures | |
| Over 87.0% of Biohaven Pharmaceutical shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Biohaven shares retains overweight rating on clinical trial |
Check out Biohaven Pharmaceutical Backtesting, Biohaven Pharmaceutical Valuation, Biohaven Pharmaceutical Correlation, Biohaven Pharmaceutical Hype Analysis, Biohaven Pharmaceutical Volatility, Biohaven Pharmaceutical History as well as Biohaven Pharmaceutical Performance. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.37) | Return On Assets (1.19) | Return On Equity (2.65) |
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.